A prophylactic approach for bone marrow transplantation from a hepatitis B surface antigen-positive donor

Sobhonslidsuk, Abhasnee; Ungkanont, Artit

doi:10.3748/wjg.v13.i7.1138

Cited by 6 publications

(3 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…1 Furthermore two case-reports have confi rmed the effi cacy of lamivudine-prophylaxis in this clinical setting in preventing HBVrelated hepatitis. 54,55 General recommendations in HSCT a. Vaccination of the recipient prior to transplant with accelerated protocols, (recombinant vaccine 40 µg by intramuscular route time 0-1-2 months or 0-7-21 days), especially if he/she is naïve. b. Vaccination of the donor not immunized prior to transplant, with accelerated protocols (recombinant vaccine 20 µg by intramuscular route time 0-1-2 months or 0-7-21 days) in the case of allogeneic HSCT.…”

Section: Oncology Hematology and Hematopoietic Stem Cell Transplantamentioning

confidence: 99%

Prophylaxis and treatment of Hepatitis B in immunocompromised patients

2008

View full text Add to dashboard Cite

The literature on hepatitis B virus (HBV) in immunocompromised patients is heterogeneous and refers mainly to the pre-antivirals era. Today a rational approach to the problem of hepatitis B in these patients provides for: a) the evaluation of HBV markers and of liver condition in all subjects starting immunosuppressive therapies (baseline), b) the treatment with antivirals (therapy) of active carriers, c) the pre-emptive use of antivirals (prophylaxis) in inactive carriers, especially if they are undergoing immunosuppressive therapies judged to be at high risk, d) the biochemical and HBsAg monitoring (or universal prophylaxis, in case of high risk immunosuppression) in subjects with markers of previous contact with HBV (HBsAg-negative and antiHBc-positive), in order to prevent reverse seroconversion.Moreover it is suggested a strict adherence to the criteria of allocation based on the virological characteristics of both recipients and donors in the general setting of transplants, and in liver transplantation the universal prophylaxis with nucleos(t) ides analogues (frequently combined with specific anti-HBV REVIEW ARTICLE24 immunoglobulins) in HBsAg-positive candidates and in HBsAgnegative recipients of antiHBc-positive grafts should be adopted.

show abstract

Section: Oncology Hematology and Hematopoietic Stem Cell Transplantamentioning

confidence: 99%

Prophylaxis and treatment of Hepatitis B in immunocompromised patients

2008

View full text Add to dashboard Cite

show abstract

“…In contrast, in a recent study the activation of therapy with lamivudine in donors and of prophylaxis with the same antiviral in recipients significantly reduced the HBV-related hepatitis rate (48 vs. 7%, P =0.002) and mortality (24 vs. 0%, P =0.01) compared to a historical control group1. Furthermore two case reports have confirmed the efficacy of lamivudine-prophylaxis in this clinical setting in preventing HBV related hepatitis55,56.…”

Section: Oncology Hematology and Hematopoietic Stem Cell Transplantamentioning

confidence: 95%

Management of HBV Infection During Immunosuppresive Treatment

Marzano¹

2009

Medit J Hemat Infect Dis

View full text Add to dashboard Cite

The literature on hepatitis B virus (HBV) in immunocompromised patients is heterogeneous and refers mainly to the pre-antivirals era. Currently, a rational approach to the problem of hepatitis B in these patients provides for: a) the evaluation of HBV markers and of liver condition in all subjects starting immunosuppressive therapies (baseline), b) the treatment with antivirals (therapy) of active carriers, c) the pre-emptive use of antivirals (prophylaxis) in inactive carriers, especially if they are undergoing immunosuppressive therapies judged to be at high risk, d) the biochemical and HBsAg monitoring (or universal prophylaxis in case of high risk immunosuppression, as in onco-haematologic patients and bone marrow transplantation) in subjects with markers of previous contact with HBV (HBsAg-negative and antiHBc-positive), in order to prevent reverse seroconversion. Moreover in solid organ transplants it is suggested a strict adherence to the criteria of allocation based on the virological characteristics of both recipients and donors and the universal prophylaxis or therapy with nucleos(t)ides analogs

show abstract

“…Previo al trasplante, es recomendable la inmunoprofilaxis del receptor con una dosis de la vacuna, seguida por la administración post-trasplante de inmuno globulina específica contra hepatitis B si hay disponibilidad de este agente biológico. Además, se recomienda el inicio de profilaxis antivírica unos días antes del trasplante y continuar esta terapia por al menos tres meses si las cargas virales permanecen indetectables [76][77][78][79] .…”

Section: Vacunas Inactivadas Y Toxoidesunclassified